Clinical Trial: Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07904494) titled 'Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma' on Oct. 18.

Brief Summary: The goal of this observational study is to evaluate how well first-line immunotherapy works and investigate its association with immune-related adverse events (irAEs) in Egyptian adults with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery.

The main questions this study aims to answer are:

* Are immune-related adverse events (irAEs), which are side effects caused by activation of the immune system, associated ...